Aimia has completed a valuation
Aimia has completed a valuation in connection with a substantial issuer bid, purchasing for cancellation CAD$150 million of shares.
Listed on the TSX, Aimia offers loyalty solutions for many of the world’s leading brands in the retail, consumer packaged goods, travel and hospitality, and financial services verticals.
Oaklins’ team in Canada was retained as a valuation expert by Aimia’s Audit Committee of the Board of Directors to provide an independent valuation in accordance with MI 61–101, and valued the common shares in the range of CAD$541–CAD$686 million.
Contáctese con el equipo de la transacción
Transacciones relacionadas
Niscon Inc. has been acquired by SGPS ShowRig
Niscon Inc. has been successfully acquired by SGPS ShowRig, a global provider of staging, rigging and automation for live entertainment. The acquisition reinforces SGPS Showrig’s commitment to pushing the boundaries of innovation in the entertainment industry. By adding Niscon’s unique motion-control technology to its portfolio, SGPS Showrig strengthens its ability to deliver cutting-edge, precision-driven solutions.
Aprenda másFairfest Media has acquired WTE Miami
Fairfest Media, organizer of OTM, the leading travel show in Asia, has acquired WTE Miami, the fastest-growing travel trade show in the USA. The acquisition marks a significant milestone in Fairfest’s global expansion, strengthening its presence in the Americas and beyond by leveraging decades of experience and leadership in Asia and India.
Aprenda másBanook, backed by Motion Equity, has acquired Fluidda
Banook Group has acquired Fluidda NV, marking a strategic expansion into advanced in-silico trials and respiratory disease modeling. Combining Banook’s expertise in cardiac safety and clinical data services with Fluidda’s AI-driven respiratory analytics creates a powerful, integrated platform. This deal strengthens Banook’s position in the contract research organization (CRO) sector, offering pharmaceutical clients broader, technology-enabled solutions to drive drug development and reduce costs.
Aprenda más